Concepedia
3
Publications
93
Citations
H-Index
2018
Active since
Affiliations
Portola Pharmaceuticals (United States)(Current)
University of Chicago
Stanford Medicine
Stanford University
University of Washington
Matt Birrell is an author at Portola Pharmaceuticals (United States).
Publications per year
2018–2019
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Greg Coffey, Jiajia Feng, Andreas Betz et al. · Clinical Cancer Research · 2018 · 38 citations
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Tatyana Feldman, Brian Hess, Michael S. Khodadoust et al. · Blood · 2019 · 30 citations
The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Tatyana Feldman, Brian Hess, Michael S. Khodadoust et al. · Blood · 2018 · 25 citations
Rows per page
1–3 of 3